alexa Human Immunodeficiency Virus: Discovery to Drug Resista
ISSN: 2329-6577

Biological Systems: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Human Immunodeficiency Virus: Discovery to Drug Resistance - A Review Update

Arpan Acharya1, Salil Vaniawala1, Harsh Parekh2, Rabindra Nath Misra3, Minal Wani4 and Pratap N Mukhopadhyaya1*
1SN Genelab, 2nd Floor, President Plaza, Tower A, Nanpura, Ring Road, Surat, Gujarat, India
2Department of Biotechnology, JJT University, Churu Jhunjhunu Road, Vidyanagari,, Chudela, Rajasthan, India
3Department of Microbiology, Padmashree Dr D Y Patil Medical College & Research Centre, Sant Tukaram Nagar, Pimpri, Pune - 411 018, Maharashtra, India
4Dr. D.Y. Patil Biotechnology and Bioinformatics Institute, Tathawade, Pune, India
Corresponding Author : Mukhopadhyaya PN
B-604, Kapil Aasmant, Pashan-Sus Road, Pashan, Pune-411 021, Maharashtra, India
Tel: +91 98811 53425
E-mail: [email protected]
Received: December 02, 2015; Accepted: January 07, 2016; Published: January 15, 2016
Citation: Acharya A, Vaniawala S, Parekh H, Misra RN, Wani M, et al. (2016) Human Immunodeficiency Virus: Discovery to Drug Resistance - A Review Update. Biol Syst Open Access 5:154. doi:10.4172/2329-6577.1000154
Copyright: © 2016 Acharya A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

Since year 1983 when Human Immunodeficiency virus (HIV) was first discovered, there has been a spectacular progress in understanding the complex biology of the virus. Drug discovery accepted the challenge to stem spread of pathogenic virus that was characterized by unparalleled ability to alter, survive and kill humans. The genetic diversity of this virus, attributed to an extraordinary rate of mutation of the genome, is now the center of most of the scientific hurdles met towards its prevention and control. While the disease caused by HIV was staged by the medical community, a range of drugs were almost simultaneously discovered to address it. This was followed by the challenge of managing the menace of HIV drug resistance. The unique mechanism of host invasion and reduction in immune strength of the victim opened an additional area of concern by way of secondary infection which is now the prominent immediate cause of death of patients. In this review we take a panoramic view of this entire scenario and discuss the need for private sector to contribute to research and development in order to keep pace with the complexity of the virus and bring about a sustained solution to the alarming disease caused by it.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords